[ad_1]
The world’s largest randomized control trial of COVID-19 therapeutics has found that the antiviral drug remdesivir from Gilead Sciences (Foster City, CA, USA) had no significant effect on patients’ chances of survival. infected.
The World Health Organization (WHO) SOLIDARITY trial that studied remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon regimens found that none of them “substantially affected mortality” or reduced the need for a ventilator. They appeared to have little or no effect on the 28-day mortality or hospital course of COVID-19 among hospitalized patients. However, Gilead has said that the WHO findings appear inconsistent with the evidence from other studies validating the clinical benefit of remdesivir.
Recently published final results from a double-blind, placebo-controlled, phase 3 ACTT-1 trial of remdesivir demonstrated that treatment with the investigational antiviral resulted in a faster recovery time than previously reported in hospitalized adults with Mild-moderate or severe COVID. -19. Results from the final ACTT-1 study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) are based on preliminary results published in May 2020, showing that remdesivir treatment resulted in consistent and clinically significant improvements across multiple evaluations. Results Compared to Placebo in COVID-19 Patients. The final results demonstrated that remdesivir treatment resulted in a faster recovery time than previously reported.
In its company statement, Gilead said it was unclear whether conclusive conclusions could be drawn from the results of the WHO study. Gilead also expressed concern that the data from the WHO global open-label trial had not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.
“The emerging data appear inconsistent with stronger evidence from multiple randomized controlled studies published in peer-reviewed journals that validate the clinical benefit of remdesivir. We are concerned that the data from this global open-label trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design, ”Gilead said in his statement.
Related links:
Gilead Sciences
